Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP

Trial Profile

Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 2X 121 (Primary)
  • Indications Carcinoma; Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Nov 2019 According to a Oncology Venture media release, the company has open a second trial site, at Guy's Hospital (London, UK) to accelerate patient accrual to the trial.
    • 12 Nov 2019 According to a Oncology Venture media release, till now 8 patients are enrolled in this study
    • 15 May 2019 Last checked against ClinicalTrials.gov: US National Institutes of Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top